Inhibiting Acid Ceramidase with Phenolphthalein Compounds as a Potential Cancer Treatment
Session Title
Other Abstracts
Faculty Mentor
T. Christian Grattan, Ph.D.
College
College of Arts and Sciences
Department
Chemistry, Physics, Geology, & the Environment
Abstract
Cancer is a prevalent issue. The most common current treatments for cancer include radiation therapy and chemotherapy. However, recent developments in cancer treatment have included targeted therapy. Targeted therapy drugs are directed at molecules in cancer cells that promote proliferation. This approach to treating cancer is more specific to cancer cells, allowing healthy cells to be unharmed. The focus of our research was to create a targeted therapy drug to inhibit acid ceramidase, an enzyme that functions in the sphingomyelin pathway. The sphingomyelin pathway creates lipids for the plasma membrane of cells. Acid ceramidase converts ceramide into sphingosine, while later in the sphingomyelin pathway, sphingosine is converted into sphingosine-1-phosphate. A high concentration of ceramide in the plasma membrane promotes apoptosis, while a high concentration of sphingosine-1-phosphate promotes cell proliferation. Many cancer cells have increased proliferation due to an overactivity of acid ceramidase. This makes acid ceramidase a promising target for targeted therapy. The goal of our study was to synthesize an effective inhibitor of acid ceramidase. Last Summer, we designed eight derivatives of phenolphthalein, each with different groups attached to the ortho position on the phenols. During summer 2022, we attempted to synthesize four additional derivatives. We tested each derivative in silico, all of which had promising results. We were able to successfully synthesize the original eight derivatives by reacting 2 equivalents of phenol with phthalic anhydride using an acid catalyst in a microwave. Future works will attempt to purify the latest four compounds and evaluate the bioavailability of all compounds using tissue culture assay
Grant Support?
Supported by an SC-INBRE grant from the National Institute for General Medical Sciences (P20GM103499).
Start Date
15-4-2023 12:00 PM
Inhibiting Acid Ceramidase with Phenolphthalein Compounds as a Potential Cancer Treatment
Cancer is a prevalent issue. The most common current treatments for cancer include radiation therapy and chemotherapy. However, recent developments in cancer treatment have included targeted therapy. Targeted therapy drugs are directed at molecules in cancer cells that promote proliferation. This approach to treating cancer is more specific to cancer cells, allowing healthy cells to be unharmed. The focus of our research was to create a targeted therapy drug to inhibit acid ceramidase, an enzyme that functions in the sphingomyelin pathway. The sphingomyelin pathway creates lipids for the plasma membrane of cells. Acid ceramidase converts ceramide into sphingosine, while later in the sphingomyelin pathway, sphingosine is converted into sphingosine-1-phosphate. A high concentration of ceramide in the plasma membrane promotes apoptosis, while a high concentration of sphingosine-1-phosphate promotes cell proliferation. Many cancer cells have increased proliferation due to an overactivity of acid ceramidase. This makes acid ceramidase a promising target for targeted therapy. The goal of our study was to synthesize an effective inhibitor of acid ceramidase. Last Summer, we designed eight derivatives of phenolphthalein, each with different groups attached to the ortho position on the phenols. During summer 2022, we attempted to synthesize four additional derivatives. We tested each derivative in silico, all of which had promising results. We were able to successfully synthesize the original eight derivatives by reacting 2 equivalents of phenol with phthalic anhydride using an acid catalyst in a microwave. Future works will attempt to purify the latest four compounds and evaluate the bioavailability of all compounds using tissue culture assay
